Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.69 |
| ▸ | CDK8 | P49336 | 5/20 | 0.60 |
| ▸ | CDK7 | P50613 | 2/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.60 |
| ▸ | CCND1 | P24385 | 1/20 | 0.60 |
| ▸ | CCNC | P24863 | 1/20 | 0.60 |
| ▸ | CDK9 | P50750 | 1/20 | 0.60 |
| ▸ | CCNH | P51946 | 1/20 | 0.60 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | MTOR | P42345 | 4/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124710 | 0.83 | PIK3CA (0.63) | RIPK1CDK8MAPK1PIK3CAMTOR | |
| SCHEMBL858525 | 0.83 | RIPK1 (1.00) | RIPK1CDK8CDK7CCNT1CCND1 | |
| SCHEMBL182642 | 0.79 | PIK3CA (0.69) | PIK3CAMTORIRAK4PIK3CDPDGFRB | |
| SCHEMBL183097 | 0.78 | MKNK1 (0.61) | PIK3CAMTORIRAK4MAP4K4PIK3CD | |
| SCHEMBL19398217 | 0.78 | IRAK4 (0.55) | RIPK1CDK8MAPK1PIK3CAMTOR | |
| SCHEMBL30368585 | 0.75 | CDK8 (1.00) | RIPK1CDK8CDK7CCNT1CCND1 | |
| SCHEMBL299518 | 0.75 | CDK8 (1.00) | RIPK1CDK8CDK7CCNT1CCND1 | |
| SCHEMBL182914 | 0.75 | MKNK1 (0.64) | PIK3CAMTORPIK3CDMKNK2PIK3CB | |
| SCHEMBL182568 | 0.74 | PIK3CA (0.48) | PIK3CAMTORMAP4K4PIK3CDCHEK2 | |
| SCHEMBL182555 | 0.73 | MKNK1 (0.66) | PIK3CAMTORIRAK4MAP4K4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | RIPK1 350/4885CDK8 321/4885CDK7 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.